Psychological Medicine, 2001, 31, 1223–1229. " 2001 Cambridge University Press
DOI : 10.1017}S0033291701004305 Printed in the United Kingdom
Treatment resistant depression and Axis I
co-morbidity
T. P E T E R S E N, " J. A. G O R D O N , A. K A N T, M. F A V A, J. F. R O S E N B A U M
A. A. N I E R E N B E R G
From the Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
ABSTRACT
Background. Treatment resistant depression (TRD) continues to present a formidable challenge to
clinicians, accounts for over half of the annual costs associated with treatment for depression and
causes great frustration to patients. Although there have been studies attempting to define TRD,
little information is available as to the cause of TRD. One suggestion is that patients with TRD have
a greater frequency of co-morbid psychiatric disorders, which explains their resistance to standard
antidepressant treatments. The objective of this study was to compare the co-morbidity of Axis I
disorders between a sample of TRD patients and a sample of non-TRD patients.
Methods. TRD and non-TRD patients, recruited from two separate antidepressant treatment
studies, were assessed for Axis I co-morbidity using the SCID-P for the DSM-III-R. Patients for the
two samples were then matched for baseline HAM-D-17 total score and gender.
Results. Results reveal that non-TRD patients had a higher rate of both lifetime and current
generalized anxiety disorder co-morbidity than did the TRD patients. No other statistically
significant differences in Axis I co-morbidity were found.
Conclusions. These findings do not support the idea that current or lifetime Axis I co-morbidity is
more common in TRD than non-TRD patients. In fact, the only statistical difference showed nonTRD patients with higher co-morbidity rates.
INTRODUCTION
Despite efforts in recent years to formulate
algorithms and guidelines for the treatment of
patients with refractory, or treatment resistant,
depression (TRD), this condition continues to
present a formidable challenge to clinicians
(Nierenberg & Amsterdam, 1990 ; Nierenberg &
White, 1990). TRD patients account for only
15–30 % of depressed patients undergoing psychiatric treatment, but represent over half of the
total annual costs associated with the treatment
of depression (Burrows et al. 1994). Because
clinicians typically use multiple mono- and polypharmacological strategies over long time
" Address for correspondence : Dr Timothy Petersen, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston,
MA 02114, USA.
periods, great frustration can develop when
patients demonstrate no or partial response.
To date, the majority of the research on TRD
has focused on how to define treatmentresistance (Nierenberg & White, 1990 ; Phillips
& Nierenberg, 1994 ; Fava et al. 1996). Initial
concerns included the possibility that many
patients labelled as treatment resistant were
simply treated with inadequate dosages of
antidepressants or took these medications for an
insufficient length of time. Greater consensus,
however, has been reached recently with respect
to defining treatment-resistance. Phillips &
Nierenberg (1994) provide dosage and plasma
levels that should be used and sustained before
considering a trial as being adequate. In addition, the same authors suggest that a medication trial of 4 to 6 weeks may not be of
sufficient duration to assess response}non-
1223
1224
T. Petersen and others
response. Trials of medications should be conducted for a minimum of 6 weeks, and up to 12
weeks if a partial response is detected. There is
less consensus, however, with respect to the
number of failed medication trials necessary
before a patient can be defined as resistant.
Some argue that failing one adequate trial
constitutes treatment-resistance, whereas others
believe multiple failed trials are necessary before
reaching this conclusion (Nierenberg, 1990).
Prior to efforts dedicated to defining TRD,
many researchers examined variables that may
be predictive of response to antidepressant
treatment. Among the factors found to be
associated with poorer outcome included : longer
current episodes, a greater level of self-reported
versus clinician-rated symptom severity,
somatization symptoms, certain co-morbid personality and Axis I disorders, the melancholic
depressive subtype, low pre-treatment cortisol
levels, blunted prolactin response to fenfluramine challenge, concurrent substance
abuse, lack of social support, neuroticism, high
reward dependence, lower levels of education,
psychomotor retardation and higher initial
symptom severity (Rush et al. 1983 ; Frank et al.
1984 ; Joyce & Paykel, 1989 ; Kocsis et al. 1989 ;
Nierenberg, 1990 ; Goodwin, 1993 ; Popescu et
al. 1993 ; Schmauss & Erfurth, 1993 ; Hoencamp
et al. 1994 ; Nelson et al. 1994 ; Phillips &
Nierenberg, 1994 ; Burns et al. 1995 ; Nelson &
Cloninger, 1995 ; Fava et al. 1996 ; Spillman et
al. 1997 ; Cleare et al. 1998 ; Flory et al. 1998 ;
Hirschfeld et al. 1998). In a study based on the
NIMH Collaborative Research Program, cognitive, social, and work dysfunction were all
predictive of poorer outcome in one or more of
the treatment groups (Sotsky et al. 1991).
Hirschfeld et al. (1998) found that living with a
partner or spouse, having more education and
having a higher quality of life were all associated
with better outcome.
Two distinct limitations do not allow the
above findings to be extrapolated for the
question of what contributes to treatment
resistance. First, the finding that the above
variables are predictive of poorer response to
treatment has not been uniformly replicated. In
fact, some researchers have found that the same
factors bear no relation to treatment response
(Joyce & Paykel, 1989 ; Kocsis et al. 1989 ;
Hirschfeld et al. 1998). Secondly, none of these
studies examined patients who had been
identified as treatment resistant prior to the
onset of treatment. Rather, status as a nonresponder was based only on the medication
trial pertinent to the prospective study in the
reports.
Some researchers have argued that, at a
conceptual level, the most logical explanation
for treatment resistance is co-morbidity of other
disorders, which compromises the effectiveness of standard antidepressant treatments
(Nierenberg & Amsterdam, 1990). For example,
if a patient suffers from both depression and
OCD, certain antidepressant treatments may be
ineffective in alleviating the entire constellation
of symptoms. In such cases, what are actually
symptoms of the co-morbid condition can
appear as unresolved depressive symptoms. This
problem is compounded by the tendency for
clinicians to overlook co-morbid conditions,
especially outside of research settings where time
and resource constraints may not allow for
formal, structured diagnostic interviews. To test
such a model formally, a comparison would
have to be made between TRD and non-TRD
patients.
There exists a clear need for a better understanding of what factors are associated with
TRD, especially compared with depression that
does not exhibit resistance to treatment. Are
there certain factors that help separate TRD as
a distinct subtype? If so, then improvements
could be made to customize treatments for this
population of patients. To this end, the objective
of this study was to compare a sample of
patients formally defined as treatment resistant
with a sample of patients not having experienced
treatment resistance. In particular, we were
interested in rates of Axis I co-morbidity between
these two samples. Our hypothesis was that
treatment resistant patients would experience
higher rates of Axis I co-morbidity, possibly
explaining their resistance to standard antidepressant treatments.
METHOD
TRD and non-TRD participants were recruited
through respective out-patient antidepressant
clinical trials at the Massachusetts General
Hospital ’s Depression Clinical and Research
Program (DCRP). Common exclusion criteria
TRD and Axis I co-morbidity
Table 1. Demographic and clinical data
Characteristic
TRD sample
Gender, N
Male
Female
39
31
78
61
23±2 years
46±5 months
27±3 years
35±0 months
0±97
1±08
Age of 1st onset
Duration of current episode,
mean
Prior episodes, mean
Non-TRD sample
for both trials were : a history of organic mental
or seizure disorder, serious or unstable medical
illness, substance abuse disorders active within
the past 12 months, acute suicidal risk (as
assessed through clinical interview and using the
HAM-D-17 and BDI), pregnancy, lactation,
bipolar disorder, psychotic disorders, history of
adverse reaction or allergy to study medications,
concomitant use of psychotropic medications,
and clinical or laboratory evidence of thyroid
abnormalities. Participants in both studies
signed Institutional Review Board (IRB) approved informed consent immediately prior to
the initial study visit.
Enrolment in the two out-patient studies was
as follows : 92 patients were enrolled between
1993 and 1999 in the TRD study and a total
of 378 patients between 1989 and 1994 were
enrolled in the non-TRD study. Because of noncompleters and insufficient data, only 70 of the
TRD patients were used in the analysis. For the
non-TRD patients 139 were used in analysis, as
two non-TRD patients were matched to each
TRD patient (process is described below). From
the available non-TRD sample, patients were
randomly selected as representative matches for
each TRD patient. Inclusion criteria for the
TRD study were as follows : men and women
ages 18 to 70 with major depressive disorder
(MDD) as diagnosed using the Structured
Clinical Interview for the DSM-III-R (SCID-P)
(Spitzer et al. 1989) ; a score on the 17-item
Hamilton Depression Rating Scale (HAM-D17) (Hamilton, 1960) of & 18 ; and at least one,
but no more than five, adequate failed medication trials during the current episode of MDD.
‘Adequacy ’ was assessed using the McLean
Hospital Antidepressant Treatment Record
(McATR) (Nierenberg, 1992), which, providing
specific criteria for adequate dosage and
duration for a trial, defines an ‘adequate trial ’
1225
as maintaining a significant dosage level (which
varies from medication to medication) of medication for at least 6 weeks. This study was
designed specifically for patients with TRD.
Clinicians conducting patient interviews were
formally trained in the use of the above instruments and scales. Inter-rater reliability, for the
use of the SCID-P in our group of clinicians
across a wide range of studies, was recently
estimated as kappa ¯ 0±80 (Fava et al. 2000).
Inclusion criteria for the non-TRD protocol
included : men and women ages 18 to 65 meeting
criteria for current MDD as defined by the
SCID-P (Spitzer et al. 1989) ; a HAM-D-17
score of & 16 at baseline ; and being completely
free of psychotropic medications for at least 2
weeks before the baseline visit. Additional
specific exclusion criteria for this study include a
past history of failure of 60 to 80 mg of fluoxetine
per day and a failure of the combination of
fluoxetine and desipramine or lithium. All
patients entering this trial did not meet criteria
for treatment-resistance during the current episode of MDD as defined in the TRD study.
Participants from both studies were matched
for baseline HAM-D-17 total score and gender
in order to minimize the effect of these variables
on comparisons of Axis I co-morbidity. Each of
the 70 TRD patients was matched as above with
two non-TRD patients, with the exception of
one TRD patient for whom only one match
could be identified in the non-TRD sample.
HAM-D-17 total scores were matched within
one point of each other (i.e. a total score of 19
for a TRD patient was matched to a non-TRD
patient total score of 18–20). The investigators
felt that given the limited number of study
subjects available in the TRD study, this was the
most effective way to detect differences between
the study groups. This method not only allowed
for comparisons between like subjects, but also
increased the overall statistical power of the
analyses.
Multiple chi-square analysis was used to
compare frequencies of Axis I disorders between
TRD and non-TRD patients as well as to
compare categorical baseline demographic and
clinical variables for which patients in the two
samples were not matched (see Table 1). Unpaired t tests were used to compare baseline
demographic and clinical variables measured in
a continuous manner.
T. Petersen and others
1226
RESULTS
Mean age for the TRD sample was 41±8 years
and for the non-TRD sample was 39±3 years
( t ¯ 1±531, P ¯ 0±1273). Table 1 depicts gender
distribution and other clinical data for both
Table 2. Frequency of medications failed in
the current depressive episode by TRD patients
Medication(s)
Received
Not received
88
26
16
26
26
16
15
14
19
0
19
4
66
76
66
66
76
77
78
73
92
73
SSRI
Effexor
MAOI
Bupropion
Tricyclic
Trazodone
Nefazodone
Remeron
Lithium augmentation
Thyroid augmentation
SSRI combination
TRD and non-TRD samples. No significant
differences were found between study groups
for any of the variables listed in Table 1. As
described previously, TRD and non-TRD
patients were matched at baseline for HAM-D17 total score and gender. Table 2 presents
frequency of types medications failed by the
patients in the TRD sample. Table 3 presents
Axis I lifetime co-morbidity data, as well as chisquare analyses, which evaluated differences in
co-morbidity between the two groups. As can
be seen from Table 3, only one statistically
significant difference existed between the two
groups – non-TRD patients had a significantly
higher rate of lifetime GAD co-morbidity than
the TRD patients. No other differences were
found to be statistically significant. Range of
Axis I lifetime co-morbidity was 4±3–30±0 % for
TRD patients and 5±0–34±5 % for non-TRD
patients. Table 4 presents Axis I current comorbidity data, as well as chi-square analyses,
Table 3. Lifetime Axis I co-morbidity
DSM diagnosis
Alcohol abuse
Other substance abuse
Panic disorder
OCD
Agoraphobia
Social phobia
Simple phobia
GAD
Somatoform disorders
Eating disorders
TRD sample
Frequency ( %)
Non-TRD sample
Frequency ( %)
χ#
21}70 (30±0)
10}70 (14±3)
12}70 (17±1)
7}70 (10±0)
8}70 (11±4)
19}70 (27±1)
9}70 (12±9)
3}70 (4±3)
6}70 (8±6)
6}70 (8±6)
47}139 (33±8)
30}139 (21±6)
17}139 (12±2)
7}139 (5±0)
9}139 (6±5)
48}139 (34±5)
19}139 (13±7)
22}139 (15±8)
7}139 (5±0)
12}139 (8±6)
0±308
1±602
0±940
1±836
1±529
1±167
0±026
0±589
0±998
0±002
P
0±6404
0±2642
0±3970
0±2398
0±2831
0±3464
" 0±9999
0±014*
0±3672
0±9999
OCD, Obsessive–compulsive disorder ; GAD, generalized anxiety disorder.
For all χ# comparisons df ¯ 1.
* P ! 0±05.
Table 4. Current Axis I co-morbidity
DSM diagnosis
Alcohol abuse
Other substance abuse
Panic disorder
OCD
Agoraphobia
Social phobia
Simple phobia
GAD
Somatoform disorders
Eating disorders
TRD sample
Frequency (%)
Non-TRD sample
Frequency (%)
χ#
2}70 (2±9)
1}70 (1±4)
6}70 (8±6)
4}70 (5±7)
4}70 (5±7)
15}70 (21±4)
6}70 (8±6)
3}70 (4±3)
4}70 (5±7)
2}70 (2±9)
8}139 (5±8)
8}139 (5±8)
10}139 (7±2)
4}139 (2±9)
7}139 (5±0)
42}139 (30±2)
19}139 (13±7)
22}139 (15±8)
6}139 (4±3)
1}139 (0±7)
0±858
2±115
0±125
1±018
0±043
1±812
1±149
5±889
0±200
1±504
OCD, Obsessive–compulsive disorder ; GAD, generalized anxiety disorder.
* P ! 0±05.
P
0±5010
0±2775
0±7849
0±4458
" 0±9999
0±1923
0±3685
0±0137*
0±7348
0±2603
TRD and Axis I co-morbidity
which evaluated differences in co-morbidity
between the two groups. As can be seen from
Table 4, one statistically significant difference
existed between the two groups – non-TRD
patients had a significantly higher rate of current
GAD co-morbidity than TRD patients had. No
other differences were found to be statistically
significant. Range of Axis I current co-morbidity
was 1±4–21±4 % for TRD patients and 0±7–30±2 %
for non-TRD patients.
DISCUSSION
To our knowledge, this is the first study to
compare Axis I co-morbidity between two
samples of depressed out-patients who had been
formally defined as treatment resistant and
non-treatment resistant. We found only one
significant difference between the two groups –
non-TRD patients had significantly higher rates
of current and lifetime GAD than the TRD
patients. Rates of Axis I lifetime co-morbidity
were found to range from 4±3–30±0 % for TRD
patients and 5±0–34±5 % for non-TRD patients.
Not only are these rates lower than found
previously in a sample of treatment resistant
unipolar patients, but they also do not support
the idea that higher rates of Axis I co-morbidity
contribute to treatment-resistance (Sharma et al.
1995).
It is important to note that some research has
been conducted to examine what factors are
associated with Axis I co-morbidity in depressed
out-patients. Recent research indicates that Axis
I co-morbidity in depressed patients may vary
with gender. Fava et al. (1996) and Carter et al.
(1999) both found that women were more likely
than men to have a lifetime history of bulimia
nervosa, while men were more likely than women
to have a history of substance abuse and
dependence. Alpert et al. (1999) found that
patients with early-onset depression had a
greater number of Axis I co-morbid conditions
when compared to patients with late-onset
depression. Tedlow et al. (1999) demonstrated
that depressed patients with anger attacks did
not differ from those without anger attacks with
respect to Axis I co-morbidity. However, the
above studies did not focus on the association
between co-morbidity and treatment-resistance.
Strengths of our study include using formal
criteria to define treatment-resistance and
1227
matching patients for gender and baseline
depression severity. Using formal TRD criteria
is especially critical given recent debate concerning what constitutes treatment-resistance.
Our use of matching patients for gender and
initial symptom severity is also critical, as these
two variables have been found to be associated
with differing rates of co-morbidity and response
to treatment. In addition, the documented interrater reliability between the physicians at the
center where the studies were conducted also
adds significant validity to the study results.
There are several possible limitations to our
study. The first is a sampling bias resulting from
respective exclusion criteria of the studies from
which patients were drawn. For example, both
studies excluded patients with concurrent substance abuse. Perhaps this led to rates of comorbid substance abuse disorders that were
lower than what would be found in general
practice. Sampling bias in a study population
also tends to lead to a sample having more
prominent occurrence of specific conditions and
characteristics than in the normal population.
Study subjects are specifically seeking out help
and may therefore present with different severity
and prevalence of symptoms and co-morbid
conditions than subjects not seeking help. In
addition, the severity of the patient’s depressive
state may have affected his}her ability to report co-morbid symptoms. It is possible that
symptoms of MDD could influence the accuracy
of a patient’s account and recall of current or
lifetime symptomatology. We also do not know
to what extent our findings may have differed if
we had examined only chronic TRD patients as
opposed to acute TRD patients. Our sample of
TRD patients was experiencing an acute major
depressive episode, but not necessarily a chronic
condition. We must also note that the fact that
the subjects were from two different studies is in
itself a shortcoming. The variety of methods and
procedures used in the two studies could have in
itself caused variability in the measures used or
it could have prevented differences from being
detected. It should also be noted that treatment
resistance was determined retrospectively rather
than prospectively. More statistical power could
be achieved in future studies by prospectively
identifying treatment resistance. The obvious
difficulty in using a retrospective analysis is the
possible bias inherent in a patient’s reporting of
1228
T. Petersen and others
failed trials, especially during an acute major
depressive episode.
There are some further limitations that are
worth noting. Given the small sample size of the
TRD patients, attempts were made to increase
statistical power by matching TRD subjects
with non-TRD subjects ; however, we would
suggest that further studies be done using larger
sample sizes before fully interpreting the
differences found here between TRD and nonTRD patients in regards to lifetime and current
rates of GAD co-morbidity. Small sample sizes
could have resulted in differences in Axis I comorbidity rates that appear clinically meaningful
(e.g. TRD OCD co-morbidity rate of 10 % v.
non-TRD OCD co-morbidity rate of 5 %), but
in fact are not statistically significant. With such
low rates of prevalence, it is possible that even a
larger sample would not increase the importance
of this finding. In addition, the TRD subjects
had a varying number of failed trials to a variety
of different medications. Because there was no
way of controlling for this variability, we do not
know what effect it may have had on the ability
of subject to report co-morbid symptoms. Often
a medication will alleviate one or more
symptoms that may or may not be related to the
depression ; these symptoms can be related to
the comorbid condition, but are often easily
confused with symptoms of depression. Because
of the small sample size of TRD patients, we
were unable to examine the effect of number of
failed trials on outcome. It is possible that a
group of TRD patients with a more homogeneous and large number of failed trials would
experience higher rates of Axis I co-morbidity.
We should note also that although we did match
patients on two important variables – age and
initial severity of depression, this study would
have been strengthened by matching on additional clinical variables, including number of
prior treatments, duration of the current episode,
first age of onset, and number of prior episodes.
Future studies should attempt to broaden
matching criteria, which will strengthen any
conclusions reached regarding differing rates of
Axis I co-morbidity.
A final issue, briefly touched on earlier,
concerns the interplay of co-morbid condition,
the treatment(s) to which a patient was resistant,
and the distinction between recovery from
depression and improvement in the co-morbid
condition(s). There is the possibility that treatments to which a given patient was resistant in
his}her current major depressive episode had an
effect on symptoms of a co-morbid condition.
For example, despite lack of an antidepressant
response to fluoxetine, a given patient’s comorbid OCD may have improved during the
course of using this medication. Similarly, a
different co-morbid condition (e.g. PTSD) may
not have improved at all under the same scenario.
It is difficult, if not impossible, to assess the
effects of such relationships between co-morbid
conditions and antidepressant medications that
patients were resistant to. This is due to the
complex permutations of such relationships,
which are beyond the scope of this paper to
formally evaluate. However, a limitation of this
study is that our ability to measure prevalence of
co-morbid conditions may have been affected by
such factors.
A related issue concerns the degree to which
depression and other co-morbid conditions are
related. Is panic disorder more closely related to
depression that PTSD? What about OCD and
social phobia? From a theoretical standpoint,
one could argue that certain conditions share
more in common (i.e. avoidant behaviour in
social phobia and withdrawn behaviour in
depression). For this reason, it is difficult to
assess whether an improvement in depressive
symptoms is because of a change in a co-morbid
condition and vice versa. Again such relationships could have affected our ability to measure
rates of co-morbidity in the current study.
The current study adds to the body of
literature concerning TRD. As reviewed by
Nierenberg & White (1990), Phillips &
Nierenberg (1994) and Fava et al. (1996),
methodology of past TRD studies varies somewhat. The most important distinction between
studies concerns whether treatment-resistance
was determined prospectively or retrospectively.
In the current study, we did so in a retrospective
fashion, to which there are obvious disadvantages that were mentioned earlier. The
other two most important factors that distinguish TRD studies from each other are type
of exclusion criteria and definition of what
constitutes a failed trial. In the current study,
patients were excluded for reasons common to
drug trials and a failed trial was formally defined
using the McATR. In previous studies of TRD,
TRD and Axis I co-morbidity
patients were not always drawn from drug trials,
but from a variety of sources. Thus exclusion
criteria varied, which can have an effect on study
outcomes. In addition, a failed trial is defined in
a much looser fashion in most previous TRD
studies, therefore creating the possibility that
such trials do not actually represent treatment
resistance.
In summary, findings from this study do not
support the idea that current or lifetime Axis I
co-morbidity occurs at higher rates in TRD v.
non-TRD patients. In fact, the only statistically
significant difference found between the two
groups was that GAD occurred at higher rates
in the non-TRD sample when compared with
the TRD sample. These findings are important
as they contribute to our knowledge base of
what factors cause or are associated with resistance to treatment. Through better understanding
of these factors, treatments can be tailored for
this sub-population of depressed patients.
This study was supported by NIMH grants R29MH46952 and R01-MH48483.
REFERENCES
Alpert, J., Pingol, M., Rankin, M., Delgado, M., Mischoulon, D.,
Nierenberg, A., Worthington, J., Sonawalla, S. & Fava, M. (1999).
Methylfolate as an Adjunct in SSRI Refractory Depression.
American Psychological Association : Washington DC.
Burns, R. A., Lock, T, Edwards, D. R. L., Katona, C. L. E.,
Harrison, D. A., Robertson, M. M., Nairac, B. & Abou-Saleh,
M. T. (1995). Predictors of response to amine-specific antidepressants. Journal of Affective Disorders 35, 97–106.
Burrows, G. D., Norman, T. R. & Judd, F. K. (1994). Definition and
differential diagnosis of treatment resistant depression. International Clinical Psychopharmacology 9, 5–10.
Carter, J. D., Joyce, P. R., Mulder, R. T., Luty, S. E. & Sullivan,
P. F. (1999). Gender differences in the rate of comorbid Axis I
disorders in depressed outpatients. Depression and Anxiety 9,
49–53.
Cleare, A. J., Murray, R. M. & O ’Keane, V. (1998). Assessment of
serotonergic function in major depression using d-fenfluramine :
relation to clinical variables and antidepressant response. Biological
Psychiatry 44, 555–561.
Fava, M., Kaji, J. & Davidson, K. (1996). Pharmacologic Strategies
for Treatment Resistant Major Depression. Challenges in Clinical
Practice : Pharmacologic and Psychosocial Strategies. Guilford
Publications : New York.
Fava, M., Alpert, J. E., Nierenberg, A. A., Russell, J., O’Boyle, M.,
Camilleri, A. & Harrison, W. A validation study of a computerized
management system system for the diagnosis and treatment
of depression. Report presented at the American Psychiatric
Association Annual Meeting, May 2000.
Flory, J. D., Mann, J. J., Manuck, S. B. & Muldoon, M. F. (1998).
Recovery from major depression is not associated with
normalization of serotonergic function. Biological Psychiatry 43,
320–326.
Frank, E., Jarrett, D. B., Kupfer, D. J. & Grochocinski, V. J. (1984).
Biological and clinical predictors of response in recurrent
depression : a preliminary report. Psychiatry Research 13, 315–324.
1229
Goodwin, F. K. (1993). Predictors of antidepressant response.
Bulletin of the Menninger Clinic 57, 146–160.
Hamilton, M. (1960). A rating scale for depression. Journal of
Neurology, Neurosurgery, and Psychiatry 23, 56–62.
Hirschfeld, R. M. A., Russell, J. M., Delgado, P. L., Fawcett, J.,
Friedman, R. A., Harrison, W. M., Koran, L. M., Miller, I. W.,
Thase, M. E., Howland, R. H., Connolly, M. A. & Miceli, R. J.
(1998). Predictors of response to acute treatment of chronic and
double depression with sertraline or imipramine. Journal of Clinical
Psychiatry 59, 669–675.
Hoencamp, E., Haffmans, P. M. J., Duivenvoorden, H., Knegtering,
H. & Dijken, W. A. (1994). Predictors of (non-) response in
depressed outpatients treated with a three-phase sequential
medication strategy. Journal of Affective Disorders 31, 235–246.
Joyce, P. R. & Paykel, E. S. (1989). Predictors of drug response in
depression. Archives of General Psychiatry 46, 89–99.
Kocsis, J. H., Mason, B. J., Frances, A. J., Sweeney, J., Mann, J. J.
& Marin, D. (1989). Prediction of response of chronic depression
to imipramine. Journal of Affective Disorders 17, 255–260.
Nelson, E. C. & Cloninger, C. R. (1995). The tridimensional
personality questionnaire as a predictor of response to nefazodone
treatment of depression. Journal of Affective Disorders 35, 51–57.
Nelson, J. C., Mazure, C. M. & Jatlow, P. I. (1994). Characteristics
of desipramine-refractory depression. Journal of Clinical Psychiatry
55, 12–19.
Nierenberg, A. A. (1990). Methodological problems in treatment
resistant depression research. Psychopharmacology Bulletin 26,
461–464.
Nierenberg, A. A. (1992). McLean Hospital Antidepressant
Treatment Record. (Unpublished report.)
Nierenberg, A. A. & Amsterdam, J. (1990). Treatment resistant
depression : definition and treatment approaches. Journal of
Clinical Psychiatry 51(suppl. 6), 39–47.
Nierenberg, A. A. & White, K. (1990). What next? A review of
pharmacologic strategies for treatment resistant depression.
Psychopharmacology Bulletin 26, 429–460.
Phillips, K. & Nierenberg, A. A. (1994). The assessment and treatment
of refractory depression. Journal of Clinical Psychiatry 55(suppl.
2), 20–26.
Popescu, C., Ionescu, R. & Jipescu, I. (1993). Predictors of the
response to tricyclic antidepressants in major depression. Romanian
Journal of Neurology and Psychiatry 31, 117–134.
Rush, A. J., Roffwarg, H. P., Giles, D. E., Schlesser, M. A., Fairchild,
C. & Tarell, J. (1983). Psychobiological predictors of antidepressant
drug response. Pharmacopsychiatry 16, 192–194.
Schmauss, M. & Erfurth, A. (1993). Prediction of antidepressant
response – critical review and perspectives. Fortschritte der
Neurologic – Psychiatric 61, 274–283.
Sharma, V., Mazmanian, D., Persad, E. & Kueneman, K. (1995). A
comparison of comorbid patterns in treatment-resistant unipolar
and bipolar depression. Canadian Journal of Psychiatry 40 (5),
270–274.
Sotsky, S. M., Glass, D. R., Shea, M. T., Pilkonis, P. A., Collins,
J. F., Elkin, I., Watkins, J. T., Imber, S. D., Leber, W. R., Moyer,
J. & Oliveri, M. E. (1991). Patient predictors of response to
psychotherapy and pharmacotherapy : findings in the NIMH
treatment of depression collaborative research program. American
Journal of Psychiatry 148, 997–1008.
Spillmann, M., Borus, J., Davidson, K., Worthington, J. J., Tedlow,
J. R. & Fava, M. (1997). Sociodemographic predictors of response
to antidepressant treatment. International Journal of Psychiatry
and Medicine 27, 129–136.
Spitzer, R. L., Williams, J. B. W., Gibbon, M. & First, M. B. (1989).
Structured Clinical Interview for DSM-III Patient Edition (SCIDP, 9}1}89 Version). Biometrics Research Department, New York
State Psychiatric Institute : New York, NY.
Tedlow, J. R., Leslie, V. C., Keefe, B. R., Alpert, J. E., Nierenberg,
A. A., Rosenbaum, J. F. & Fava, M. (1999). Axis I and Axis II
disorder comorbidity in unipolar depression with anger attacks.
Journal of Affective Disorders 52, 217–223.